問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University Hospital (在職)

Division of Thoracic Medicine

Linkou Chang Gung Medical Foundation (在職)

Division of Thoracic Medicine

更新時間：2023-09-19

周俊良Chou, Chun-Liang
  • Principal Investigator
  • Clinical Trial Experience (year) 13 years 1 個月

Recruiting Trial

24Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

周俊良

List

34Cases

2025-09-01 - 2028-09-01

Phase I/II

Completed
A Phase 1/2 first-in-human trial of DCC-3116 as monotherapy and in combination with a RAS/MAPK pathway inhibitor in patients with advanced or metastatic solid tumors harboring RAS/MAPK pathway mutations.

  • Condition/Disease

    Advanced or metastatic solid tumors with RAS/MAPK pathway mutations

  • Test Drug

    DCC-3116

Participate Sites
4Sites

Recruiting4Sites

2025-09-22 - 2029-03-18

Active
The master plan for an open-label, multi-drug, multicenter, phase II trial evaluates the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity (LIBRA) of a novel combination therapy in participants with locally advanced or metastatic non-small cell lung cancer.

  • Condition/Disease

    • Safety: Number of participants experiencing adverse events (AEs) and serious adverse events (SAEs). • Efficacy: Objective response rate (ORR).

  • Test Drug

    Dato-DXd Rilvegostomig Xinruize

Participate Sites
9Sites

Recruiting9Sites

2021-09-01 - 2023-04-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting6Sites

Terminated2Sites

2023-12-01 - 2027-12-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2005-12-01 - 2007-12-01

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2023-09-01 - 2029-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2018-11-02 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

郭漢彬
Taipei Medical University Hospital

Division of Thoracic Medicine

2023-02-01 - 2026-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2020-06-01 - 2029-05-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2022-07-11 - 2026-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB